GSK press releases
Follow
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung cancer
Regulatory designation based on promising preliminary clinical data.
